Lipitor-Zetia combo-pill planned

Share this article:
Merck/Schering-Plough says it plans to sell its Zetia cholesterol inhibitor in combination with a generic version of Pfizer’s Lipitor. The pill could be available once US and international patents expire for Lipitor (atorvastatin), which could be as early as 2010. Lipitor had 2006 global sales of about $12.9 billion, according to Pfizer. The MSP joint venture already markets Zetia in a combination pill with Zocor. That drug, Vytorin, had 2006 global sales of $1.96 billion. Vytorin uses a dual approach to the treatment of high cholesterol, blocking cholesterol absorption in the small intestine (Zetia) and lowering production in the liver (Zocor). Considering Lipitor is more widely prescribed and studies show it is more effective than Zocor, the planned pill could prove even more successful, notes Bloomberg. The companies said they tested a Zetia-Lipitor combination and found that co-administration of the drugs lowered LDL or “bad” cholesterol by an average of 53% to 61%, compared to average LDL cholesterol reductions of 37% to 54% with atorvastatin alone.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...